# Genentech, Inc.: Phase 1 study closed enrollment, 165 enrolled (Locally Advanced or Metastatic Solid Tumors, NSCLC)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Genentech, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors |
| NCT ID | NCT05581004 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Locally Advanced or Metastatic Solid Tumors; NSCLC; HNSCC; Melanoma; TNBC; Esophageal Cancer |
| Intervention types | drug |
| Target enrollment | 165 |
| Site countries | United States, Australia, Belgium, Canada, Greece, Netherlands, South Korea, Spain, Taiwan |
| Posted | 2022-10-14 |
| Planned start | 2022-10-20 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 165 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05581004). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.